@article{LauthHoelderichWagenblast1995, author = {Lauth, Jakob and Hoelderich, W. and Wagenblast, G.}, title = {Crystalline zeolites containing indigo dyes}, series = {Zeolites. 15 (1995), H. 1}, journal = {Zeolites. 15 (1995), H. 1}, isbn = {0144-2449}, pages = {86}, year = {1995}, language = {en} } @article{BiselliNollJelineketal.2002, author = {Biselli, Manfred and Noll, Thomas and Jelinek, Nanni and Schmidt, Sebastian}, title = {Cultivation of Hematopoietic Stem and Progenitor Cells: biochemical Engineering Aspects / Thomas Noll, Nanni Jelinek, Sebastian Schmidt, Manfred Biselli und Christian Wandrey}, series = {Tools and Applications of Biochemical Engineering Science}, journal = {Tools and Applications of Biochemical Engineering Science}, publisher = {Springer}, address = {Berlin}, isbn = {3-540-42250-1}, pages = {111 -- 128}, year = {2002}, language = {en} } @article{BiselliHilbertNoll2001, author = {Biselli, Manfred and Hilbert, U. and Noll, T.}, title = {Cultivation of Human HCMV Specific Lymphocytes - An Example for Adoptive Immunotherapy / Hilbert, U. ; Biselli, M. ; Noll, T.}, series = {Animal cell technology : from target to market ; Tyl{\"o}sand, Sweden, June 10 - 14, 2001 / ed. by E. Lindner-Olsson ...}, journal = {Animal cell technology : from target to market ; Tyl{\"o}sand, Sweden, June 10 - 14, 2001 / ed. by E. Lindner-Olsson ...}, publisher = {Kluwer}, address = {Dordrecht}, isbn = {1-4020-0264-5}, pages = {558 -- 561}, year = {2001}, language = {en} } @article{Schnitzler2009, author = {Schnitzler, Thomas}, title = {Cultivation of hybridoma cell line CF-10H5 (DSMZ ACC477)}, series = {Application notes / Sartorius stedim biotech}, journal = {Application notes / Sartorius stedim biotech}, pages = {1 -- 4}, year = {2009}, language = {en} } @book{LauthDingerdissenSteuerle1996, author = {Lauth, Jakob and Dingerdissen, Uwe and Steuerle, Ulrich}, title = {Cup catalyst and process for producing aziridines : [Internationale Pantentanmeldung WO9633018] ; Ver{\"o}ffentlichungsdatum: 1996-10-24 / Anmelder: BASF AG ; Dingerdissen, Uwe ; Lauth, Guenther ; Steuerle, Ulrich. Erfinder: Dingerdissen, Uwe ; Lauth, Guenther ; Steuerle, Ulrich}, publisher = {[Weltorganisation f{\"u}r geistiges Eigentum]}, address = {[Genf]}, year = {1996}, language = {en} } @article{HendersonMclaughlinScheeretal.2015, author = {Henderson, Colin J. and Mclaughlin, Lesley A. and Scheer, Nico and Stanley, Lesley A. and Wolf, C. Roland}, title = {Cytochrome b5 Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo s}, series = {Molecular Pharmacology}, volume = {87}, journal = {Molecular Pharmacology}, number = {4}, publisher = {ASPET}, address = {Bethesda}, issn = {1521-0111}, doi = {10.1124/mol.114.097394}, pages = {733 -- 739}, year = {2015}, language = {en} } @article{FeuerriegelKloseSloboshaninetal.1994, author = {Feuerriegel, Uwe and Klose, W. and Sloboshanin, S. and Goebel, H. [u.a.]}, title = {Deactivation of a palladium-supported alumina catalyst by hydrogen sulfide during the oxidation of methane}, series = {Langmuir: the ACS journal of surfaces and colloids. 10 (1994), H. 10}, journal = {Langmuir: the ACS journal of surfaces and colloids. 10 (1994), H. 10}, isbn = {0743-74363}, pages = {3567 -- 3570}, year = {1994}, language = {en} } @article{ScheerKapelyukhRodeetal.2015, author = {Scheer, Nico and Kapelyukh, Yury and Rode, Anja and Oswald, Stefan and Busch, Diana and Mclaughlin, Lesley A. and Lin, De and Henderson, Colin J. and Wolf, C. Roland}, title = {Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model}, series = {Drug Metabolism and Disposition}, volume = {43}, journal = {Drug Metabolism and Disposition}, number = {11}, publisher = {ASPET}, address = {Bethesda}, issn = {1521-009x}, doi = {10.1124/dmd.115.065656}, pages = {1679 -- 1690}, year = {2015}, language = {en} } @article{KapelyukhHendersonScheeretal.2019, author = {Kapelyukh, Yury and Henderson, Colin James and Scheer, Nico and Rode, Anja and Wolf, Charles Roland}, title = {Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 KO mice}, series = {Drug Metabolism and Disposition}, journal = {Drug Metabolism and Disposition}, number = {Early view}, doi = {10.1124/dmd.119.087718}, pages = {43 Seiten}, year = {2019}, language = {en} } @article{ScheerMclaughlinRodeetal.2014, author = {Scheer, Nico and Mclaughlin, Lesley A. and Rode, Anja and MacLeod, Alastair Kenneth and Henderson, Colin J. and Wolf, Roland C.}, title = {Deletion of thirty murine cytochrome P450 genes results in viable mice with compromised drug metabolism}, series = {Drug Metabolism and Disposition}, volume = {42}, journal = {Drug Metabolism and Disposition}, number = {6}, publisher = {ASPET}, address = {Bethesda, Md.}, issn = {1521-009X}, doi = {10.1124/dmd.114.057885}, pages = {1022 -- 1030}, year = {2014}, abstract = {In humans, 75\% of all drugs are metabolized by the cytochrome P450-dependent monooxygenase system. Enzymes encoded by the CYP2C, CYP2D, and CYP3A gene clusters account for ∼80\% of this activity. There are profound species differences in the multiplicity of cytochrome P450 enzymes, and the use of mouse models to predict pathways of drug metabolism is further complicated by overlapping substrate specificity between enzymes from different gene families. To establish the role of the hepatic and extrahepatic P450 system in drug and foreign chemical disposition, drug efficacy, and toxicity, we created a unique mouse model in which 30 cytochrome P450 genes from the Cyp2c, Cyp2d, and Cyp3a gene clusters have been deleted. Remarkably, despite a wide range of putative important endogenous functions, Cyp2c/2d/3a KO mice were viable and fertile, demonstrating that these genes have evolved primarily as detoxification enzymes. Although there was no overt phenotype, detailed examination showed Cyp2c/2d/3a KO mice had a smaller body size (15\%) and larger livers (20\%). Changes in hepatic morphology and a decreased blood glucose (30\%) were also noted. A five-drug cocktail of cytochrome P450 isozyme probe substrates were used to evaluate changes in drug pharmacokinetics; marked changes were observed in either the pharmacokinetics or metabolites formed from Cyp2c, Cyp2d, and Cyp3a substrates, whereas the metabolism of the Cyp1a substrate caffeine was unchanged. Thus, Cyp2c/2d/3a KO mice provide a powerful model to study the in vivo role of the P450 system in drug metabolism and efficacy, as well as in chemical toxicity.}, language = {en} }